|
Products evaluated by NICE |
|||||
| Trade Name (England) |
Active Ingredient |
Formulation |
Cost/Daily Dose1 |
Assumed Total Daily Dose |
Daily Dosage Schedule |
|
|
|||||
| Dexedrine |
Dex amphetamine |
Short-acting |
₤ 0.43 |
20 mg/d |
2 (-3) times |
| Ritalin |
Methyl phenidate |
Short-acting |
₤ 0.56 |
30 mg/d |
3 (2–4) times |
| Equasym |
Methyl phenidate |
Short-acting |
₤ 0.53 |
30 mg/d |
3 (2–4) times |
| Concerta XL |
Methyl phenidate |
Long-acting (~12 h) |
₤ 1.23 |
36 mg/d |
1 time |
| Equasym XL |
Methyl phenidate |
Long-acting (~8 h) |
₤ 1.17 |
30 mg/d |
1 time |
| Strattera |
Atomoxetine |
Long-acting |
₤ 1.95 |
Irrelevant (flat pricing) |
1 (-2) times |
|
1Acquisition costs of the National Health Service (NHS) in England (net prices, excluding VAT and not accounting for negotiated procurement discounts in some settings), from British National Formulary 51, March 2006; note that individual doses and thus costs may vary. Assumed average doses should not be confused with dose recommendations. | |||||
Schlander Child and Adolescent Psychiatry and Mental Health 2008 2:1 doi:10.1186/1753-2000-2-1 |
|||||